Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis

B Rocca, KAA Fox, RA Ajjan, F Andreotti… - European heart …, 2018 - academic.oup.com
The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

Anticoagulation: low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and …

EA Nutescu, SA Spinier… - Annals of …, 2009 - journals.sagepub.com
Objective To develop practical recommendations for the use of low-molecular-weight
heparins (LMWHs) as prophylaxis and treatment of venous thromboembolism and acute …

Cancer-associated venous thromboembolic disease, version 2.2021, NCCN clinical practice guidelines in oncology

MB Streiff, B Holmstrom, D Angelini, A Ashrani… - Journal of the National …, 2021 - jnccn.org
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated
Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of …

Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial

RD Hull, SM Schellong, VF Tapson… - Annals of internal …, 2010 - acpjournals.org
Background: Extended-duration low-molecular-weight heparin has been shown to prevent
venous thromboembolism (VTE) in high-risk surgical patients. Objective: To evaluate the …

Venous thromboembolism prophylaxis in hospitalized patients: a clinical practice guideline from the American College of Physicians

A Qaseem, R Chou, LL Humphrey… - Annals of internal …, 2011 - acpjournals.org
Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on prophylaxis of venous …

Cancer-associated venous thromboembolic disease, version 1.2015

MB Streiff, B Holmstrom, A Ashrani… - Journal of the National …, 2015 - jnccn.org
The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline
strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients …

Anti-cancer properties of low-molecular-weight heparin: preclinical evidence

SA Mousa, LJ Petersen - Thrombosis and haemostasis, 2009 - thieme-connect.com
Malignant conditions are frequently associated with a hypercoaguable state, with recurrent
thrombosis due to the impact of cancer cells and chemotherapy or radiotherapy on the …

[HTML][HTML] The anti-factor Xa range for low molecular weight heparin thromboprophylaxis

MY Wei, SM Ward - Hematology reports, 2015 - pmc.ncbi.nlm.nih.gov
Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and
treatment of venous thromboembolism. In some patients receiving therapeutic doses of …

Venous thromboembolism prophylaxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical …

FA Lederle, D Zylla, R MacDonald… - Annals of internal …, 2011 - acpjournals.org
Background: Venous thromboembolism prophylaxis has been recommended for
nonsurgical patients, but its effectiveness remains uncertain. Purpose: To assess the …

Risk of venous thromboembolism and efficacy of thromboprophylaxis in hospitalized obese medical patients and in obese patients undergoing bariatric surgery

AT Rocha, ÂG de Vasconcellos, ER da Luz Neto… - Obesity Surgery, 2006 - Springer
Background: Obesity is considered a highly prevalent risk factor for venous
thromboembolism (VTE) in hospitalized patients. However, recommendations for VTE …